Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00555152|
Recruitment Status : Completed
First Posted : November 7, 2007
Results First Posted : November 25, 2015
Last Update Posted : April 20, 2018
|Condition or disease||Intervention/treatment||Phase|
|Ductal Breast Carcinoma In Situ HER2/Neu Positive||Other: Laboratory Biomarker Analysis Drug: Lapatinib Ditosylate Other: Placebo||Not Applicable|
I. Determine whether lapatinib (lapatinib ditosylate) therapy at the dose of 1000 mg results in a statistically significantly lower rate of proliferation in ductal carcinoma in situ (DCIS) breast cancer cells as measured by Ki67 when compared to placebo.
II. Determine the toxicity profile and frequency of adverse events in women with DCIS breast cancer taking lapatinib at 1000 mg as compared to women taking placebo.
I. Determine whether lapatinib treatment affects the incidence of DCIS seen at the time of surgical excision.
II. Determine whether treatment with lapatinib will modulate breast tissue histology or the expression of specific biomarkers in normal and DCIS breast cancer cells.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive lapatinib ditosylate orally (PO) once daily (QD) for 2-6 weeks until the time of surgery.
ARM II: Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
After completion of study treatment, patients are followed for 4-5 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer|
|Actual Study Start Date :||August 19, 2009|
|Actual Primary Completion Date :||August 28, 2014|
|Actual Study Completion Date :||August 28, 2014|
Experimental: Arm I (lapatinib ditosylate)
Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Other Name: Tykerb
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
Other: Laboratory Biomarker Analysis
- Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS) [ Time Frame: 2-6 weeks from baseline to surgery, up to 6 weeks ]Reduction in percent of Ki67 positive cells at surgery compared to baseline as a function of treatment. Analysis of the primary treatment comparison will be based on a two sample t-test comparing change in log-transformed Ki67% for placebo and treated subjects. P-values of 0.05 will be considered significant. Proliferation will be assessed by immunohistochemical (IHC) staining for Ki67, and the change in percentage of Ki67 positive cells will be compared in lapatinib-treated samples versus placebo.
- Incidence of Adverse Events Graded According to the National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) Version 3.0 [ Time Frame: From baseline to 4-5 weeks after surgery ]Toxicity profile summarized reflects incidence by number of participants affected with adverse events by Maximum Grade 1 to 3, additional adverse event according to the NCI CTCAE version 3.0 reported in Adverse Event section results.
- Incidence of Ductal Carcinoma in Situ Remaining at Resection [ Time Frame: 2-6 weeks from baseline to surgery, up to 6 weeks ]Number of participants with DCIS incidence on surgical excision. Differences in histologic response (disappearance of DCIS) will be evaluated using Fisher's exact test. Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment. All statistical tests will be two-sided.
- Biomarker Analysis of Proliferation Markers [ Time Frame: 2-6 weeks from baseline to surgery, Up to 6 weeks ]Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment. All statistical tests will be two-sided.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00555152
|United States, Alabama|
|University of Alabama at Birmingham Cancer Center|
|Birmingham, Alabama, United States, 35233|
|United States, Texas|
|M D Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Powel Brown||M.D. Anderson Cancer Center|